Boehringer Ingelheim Pharmaceuticals, Inc.

RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the ... read more

RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition to COMBIVENT(®) RESPIMAT(® )(ipratropium bromide and albuterol) ... read more

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be ... read more

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of ... read more

RIDGEFIELD, Conn., May 7, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results of two surveys that explored how pulmonologists and pathologists are incorporating biomarker testing into the care of patients with lung cancer. The results point to an increased role of these physicians in biomarker testing as ... read more

RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced three important updates to the U.S. prescribing information for PRADAXA, an oral anticoagulant (OAC) indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). -- The ... read more

RIDGEFIELD, Conn., April 23, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 STARTVerso(TM)1 trial of faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin (PegIFN/RBV). In previously untreated patients with genotype-1 hepatitis C virus (HCV) who received once-daily faldaprevir plus PegIFN/RBV, 79% ... read more

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso(TM) 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress(TM) 2013: 48th Annual Meeting of the European Association for ... read more

RIDGEFIELD, Conn., March 18, 2013 /PRNewswire/ -- A new perspective from the U.S. Food and Drug Administration (FDA) states the agency has not changed its recommendations regarding Pradaxa(®) (dabigatran etexilate mesylate) capsules, following the November 2012 Mini-Sentinel evaluations. The FDA stated that bleeding rates associated with new use of PRADAXA ... read more

RIDGEFIELD, Conn., March 4, 2013 /PRNewswire/ -- Today Boehringer Ingelheim Pharmaceuticals, Inc. announced the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso(TM). These results, from the Phase 3 trial STARTVerso(TM) 4, were presented today at the 20(th) annual Conference on ... read more

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDY(SM) and RE-SONATE(®), show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine. VTE is the third most common cardiovascular ... read more

RIDGEFIELD, Conn., Jan. 17, 2013 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc. announced that the first patients have been enrolled in the company's pivotal Phase 3 interferon (IFN)-free hepatitis C (HCV) clinical trial program, HCVerso(TM). Boehringer Ingelheim's investigational IFN-free regimen combines the compounds faldaprevir (BI 201335), a protease inhibitor administered ... read more

RIDGEFIELD, Conn., Jan. 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for ... read more

RIDGEFIELD, Conn., Dec. 19, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa® (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement. The decision to add the contraindication was made following an ... read more

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for ... read more

RIDGEFIELD, Conn., Dec. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two new post-hoc sub-analyses comparing the clinical management and outcomes of patients who experienced major bleeding while treated with dabigatran or warfarin. These findings from the RE-LY® trial and four other Phase III trials report ... read more

RIDGEFIELD, Conn., Nov. 29, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54(th) American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. Data include results from the Phase II ... read more